COR Cencora

  • Official Name: Cencora, Inc.
  • Headquarters: 1 West First Avenue, CONSHOHOCKEN, PA, 19428 US
  • CEO: Robert P. Mauch
  • Website: amerisourcebergen.com

Match Results

Date League Week Opponent Result Score
2025-07-15 1R Lost by 0.359 (0.443) - (0.084)
2025-07-17 1 Lost by 2.578 (1.163) - 1.415
2025-07-24 2 Lost by 1.552 (2.004) - (0.452)
2025-07-31 3 Lost by 7.913 (4.017) - 3.896
2025-08-07 4 Lost by 8.007 (2.758) - 5.249
2025-08-07 1R Lost by 1.184 (1.215) - (0.031)
2025-08-14 5 Won by 7.757 6.873 - (0.884)
2025-08-21 6 Won by 4.465 2.446 - (2.019)
2025-08-28 7 Won by 3.000 3.000 - 0.000
2025-09-04 8 Won by 1.478 0.923 - (0.555)
2025-09-11 9 Won by 4.364 3.214 - (1.150)
2025-09-18 10 Lost by 4.272 (4.051) - 0.221
2025-09-25 11 Won by 8.362 2.220 - (6.142)
2025-10-02 12 Lost by 3.812 3.243 - 7.055
2025-10-09 13 Lost by 0.244 1.867 - 2.111
2025-10-16 14 Lost by 3.342 1.825 - 5.167
2025-10-23 15 Won by 2.606 3.072 - 0.466

Latest News

Cencora (COR): 3 Reasons We Love This Stock
Yahoo - 2026-10-16

Cencora (COR): 3 Reasons We Love This Stock 🔗

Cencora has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 6% to...

Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In?
Yahoo - 2026-10-16

Is Cencora (COR) Undervalued Or Is Raised Guidance Already Priced In? 🔗

Cencora has delivered a powerful long run for shareholders, and the question now is whether the current share price lines up with the cash the busines...

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-15

AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? 🔗

AbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readout...

AI Disruption May Benefit Cencora More Than Hims & Hers
SeekingAlpha - 2026-10-14

AI Disruption May Benefit Cencora More Than Hims & Hers 🔗

Cencora (COR) may gain from AI-driven prescribing volume growth; with strong operating leverage and discounted P/E, see risks and $365 target—rea...

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo - 2026-10-12

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? 🔗

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

Show more
SeekingAlpha - 2026-05-09

What Moved Markets This Week 🔗